130 related articles for article (PubMed ID: 15685452)
1. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
de Jonge ME; Huitema AD; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 May; 55(5):507-10. PubMed ID: 15685452
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
3. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
4. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
5. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
7. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
9. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
[TBL] [Abstract][Full Text] [Related]
10. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate.
van Maanen MJ; Huitema AD; Beijen JH
Anticancer Res; 2000; 20(3A):1711-6. PubMed ID: 10928097
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
[TBL] [Abstract][Full Text] [Related]
12. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
[TBL] [Abstract][Full Text] [Related]
15. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL
Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593
[TBL] [Abstract][Full Text] [Related]
16. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
[TBL] [Abstract][Full Text] [Related]
17. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
[TBL] [Abstract][Full Text] [Related]
18. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]